1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp.

ATTBF
Abattis Bioceuticals Corp.US flagOther OTC
0.00
USD
- -
- -
14,334.00Market Cap
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.26
-0.15
-0.14
-0.09
-0.04
-0.16
-0.06
-0.02
-0.05
-0.24
-0.01
-0.01
Free Cash Flow per Basic Share
- -
-2.41
-0.06
-0.05
-0.03
-0.01
-0.05
-0.03
-0.01
-0.01
-0.03
0.01
0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.08
-1.59
-0.22
-0.26
-0.32
-0.18
-0.19
-0.19
- -
- -
0.03
0.03
0.03
Tangible Book Value per Share
-0.14
0.4
-0.02
-0.01
-0.01
-0.02
0.03
-0.01
-0.01
0.01
0.03
-0.01
-0.01
Basic Weighted Avg Shares
- -
- -
5
10
11
26
49
69
95
149
323
470
468
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
-5,902.26
-95,292.85
-3,347.57
- -
- -
-189,114.18
-1,125.03
-1,125.03
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-1
-1
-1
-1
-8
-4
-2
-8
-78
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-6,318.72
-98,049.37
-4,864.64
- -
- -
-931,940.11
-852.4
-852.4
Working Capital
- -
- -
- -
- -
-1
-1
1
-1
-1
- -
10
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
1
- -
1
1
1
5
- -
- -
1
11
11
11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-27.92
-27.92

Capital Structure

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
478
478
478
Market Capitalization
20
17
11

Working Capital

FRC

•

in mil. unless spec.
Mar'19
Jun'19
Sep'19
Total Current Assets
6
5
4
Cash, Cash Equivalents & STI
5
3
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
5
5
Payables & Accruals
- -
4
3
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
220.41%
291.3%
-3.87%
Free Cash Flow
125.15%
58.05%
-151.11%
Net Income, GAAP
271.58%
192.7%
-96.1%
Sales/Revenue/Turnover
- -
- -
4,163.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
-0.01
-0.01
-0.01
- -
-0.05
2018
-0.03
-0.04
-0.02
- -
-0.24
2019
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Francesco Paolini
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
625 Howe Street Vancouver BC Canada V6C 2M6
IPO Date
May 29, 2014
Website
abattis.com
Similar Companies
ECS Botanics Holdings Ltd (ECS.AX)
Avant Brands Inc. (AVNT.TO)
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ)
Cyfuse Biomedical K.K. (4892.T)
Achyut Healthcare Limited (ACHYUT.BO)
BNC Korea Co., Ltd. (256840.KQ)
Business
Abattis Bioceuticals Corp. (ATTBF) operates as a Canadian biotechnology company focused on the extraction, purification, and formulation of cannabinoids for medicinal and recreational markets; it develops and licenses natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic sectors. The company offers core products and services including high-purity distillates, isolates, and winterized oils derived from hemp and cannabis biomass using proprietary extraction techniques at its cGMP-compliant facility; contract extraction and white-label manufacturing for licensed producers; finished formats such as vape cartridges, tinctures, edibles, and water-soluble cannabinoid powders; cannabinoid-enhanced nutraceuticals like Comfort for pain and inflammation; analytical testing through subsidiary Northern Vine Labs; and export of organic CBD isolate via subsidiary Vergence Visionary Bioceuticals. Headquartered in Vancouver, British Columbia, and founded in 1997, Abattis holds Health Canada licenses for cultivation and processing, serves clients primarily in Canada with strategic partnerships targeting Europe and Latin America, and maintains an in-house R&D team for novel delivery systems alongside quality assurance testing for potency, terpenes, and solvents. Recent developments include growth through acquisitions such as the 2018 purchase of LightRail Health Sciences' extraction assets and leadership under CEO Nelson Bocella, who brings expertise in pharmaceutical manufacturing.